DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
” - 1 Victoria Garfield - 1 Tara Spires - 1 Jones - 1 Valentina Paz - 1 they’re - 1 Paz - 1 MoMo - 1
Top related locs:
Republic of Uruguay Tucson , Arizona University of Southern California
Top related orgs:
CNN - 1 University College London - 1 UCL - 1 University of - 1 British Neuroscience Association - 1 Centre - 1 Discovery Brain Sciences - 1 University of Edinburgh - 1

Search resuls for: "Tara Spires"


3 mentions found


☆ Daytime naps may be good for our brains, study says
  + stars: | 2023-06-20 | by ( Jack Guy | ) edition.cnn.com   time to read: +5 min
CNN —Taking daytime naps may help maintain brain health as we age, according to a new study. The results show “a small but significant increase in brain volume in people who have a genetic signature associated with taking daytime naps,” she told the Science Media Centre. “Even with those limitations, this study is interesting because it adds to the data indicating that sleep is important for brain health,” she said. MoMo Productions/Digital Vision/Getty ImagesHowever, such a technique can only show an association between nap and brain health, not cause and effect. Grandner directs the Behavioral Sleep Medicine Clinic at the Banner-University Medical Center in Tucson, Arizona, and was not involved in the study.
Persons: ”, Victoria Garfield, Tara Spires, Jones, Valentina Paz, they’re, Paz, MoMo, Michael Grandner, Grandner, Raj Dasgupta, “ Organizations: CNN, University College London, UCL, University of, British Neuroscience Association, Centre, Discovery Brain Sciences, University of Edinburgh, Science Media, Sleep Health, Alzheimer’s Association, Sleep Medicine, Banner - University Medical Center, Keck School of Medicine, University of Southern Locations: Republic of Uruguay, Tucson , Arizona, University of Southern California
☆ Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns
  + stars: | 2022-11-29 | by ( Jacqueline Howard | ) edition.cnn.com   time to read: +11 min
It involved 1,795 adults, ages 50 to 90, with mild cognitive impairment due to early Alzheimer’s disease or mild Alzheimer’s disease-related dementia. Such a score is consistent with early Alzheimer’s disease, with a higher number associated with more cognitive impairment. By 18 months, the CDR-SB score went up 1.21 points in the lecanemab group, compared with 1.66 in the placebo group. Overall, there were serious adverse events in 14% of the lecanemab group and 11.3% of the placebo group. The researchers also wrote that about 0.7% of participants in the lecanemab group and 0.8% of those in the placebo group died, corresponding to six deaths documented in the lecanemab group and seven in the placebo group.
☆ Analysis: Alzheimer's drug trial breakthrough boost for Roche, Eli Lilly
  + stars: | 2022-09-28 | by ( Natalie Grover | ) www.reuters.com   time to read: +5 min
Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Nearly all Alzheimer's drugs, including those targeting amyloid, have stumbled in trials. Late-stage data on gantenerumab is expected by the fourth quarter, Roche said in a statement, saying it was encouraged by the lecanemab data. Results of a key late-stage trial testing the drug are anticipated by mid-2023. AMYLOID HYPOTHESISSome researchers, including Frederiksen, are cautiously optimistic about the impact the Biogen, Eisai data has on the likelihood of success for the other two drugs in development.
0 next >>
Total: 3